샘플 요청 목록

 카트 문의
시장보고서
상품코드
1780774

세계의 파브리병 치료 시장

Fabry Disease Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 367 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

파브리병 치료 세계 시장은 2030년까지 44억 달러에 달할 전망

2024년에 27억 달러로 추정되는 파브리병 치료 세계 시장은 분석 기간인 2024-2030년에 CAGR 8.2%로 성장하여 2030년에는 44억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 효소보충요법은 CAGR 10.8%를 기록하며 분석 기간 종료시에는 17억 달러에 달할 것으로 예측됩니다. 샤프롱 치료 분야의 성장률은 분석 기간 동안 CAGR 6.4%로 추정됩니다.

미국 시장은 7억 3,780만 달러로 추정, 중국은 CAGR 13.2%로 성장 예측

미국의 파브리병 치료 시장은 2024년에 7억 3,780만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 9억 5,860만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 13.2%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.0%와 8.0%로 예측됩니다. 유럽에서는 독일이 CAGR 5.5%로 성장할 것으로 예측됩니다.

세계의 파브리병 치료 시장 - 주요 동향과 촉진요인 정리

파브리병이란 무엇이며, 왜 효과적인 치료가 중요한가?

파브리병은 GLA 유전자의 돌연변이로 인해 α&-갈락토시다아제 A(α&-Gal A) 효소의 결핍을 초래하는 희귀 유전병입니다. 이 효소는 글로보트리아오실세라미드(Gb3 또는 GL-3)라는 지방 물질을 분해하는 데 중요한 역할을 합니다. 이 효소가 부족하거나 완전히 결핍되면 심장, 신장, 신경계 등 주요 장기에 유해한 지질이 축적되어 생명을 위협하는 합병증을 유발할 수 있습니다. 파브리병은 진행성이기 때문에 조기에 효과적인 치료를 하는 것이 증상을 관리하고 장기 손상을 지연시키며 환자의 삶의 질을 개선하는 데 중요합니다.

파브리병의 치료는 주로 결핍된 효소를 보충하거나 강화하여 질병의 진행을 늦추고 관련 증상을 관리하는 데 중점을 둡니다. 역사적으로 효소대체요법(ERT)이 표준 치료법이었으며, 아갈시다제 알파(Replagal)와 아갈시다제 베타(Fabrazyme)와 같은 FDA 승인 치료제가 Gb3 축적을 억제하는 데 도움이 되었습니다. 그러나 고가의 비용, 면역반응, 잦은 정맥주사 등의 한계로 인해 샤페론요법, 기질감소요법(SRT) 등의 대체요법 개발이 진행되고 있습니다. 또한, 최근 유전자 치료의 도입은 일회성 치료법으로서 장기적인 질병 관리에 대한 희망을 가져다 줄 수 있습니다.

유전자 및 분자 치료의 발전은 어떤 변화를 가져올 것인가?

유전자 치료는 파브리병 치료에서 가장 유망한 분야 중 하나로 떠오르고 있습니다. 기존의 효소 대체 요법과 달리 유전자 치료는 GLA 유전자의 기능적 사본을 환자 세포에 주입하여 근본적인 유전적 결함을 교정하는 것을 목표로 합니다. FLT190과 AVROBIO의 AVR-RD-01과 같은 임상시험 중인 치료제는 지속적인 효소 활성과 Gb3 수준의 감소를 보여 주는 등 임상시험에서 이미 유망한 결과를 보여주고 있습니다. 이 치료법은 평생 효소 주사를 맞을 필요 없이 단 한 번의 치료로 완치될 수 있는 가능성을 가지고 있습니다.

치료의 또 다른 큰 혁신은 약리학적 샤페론 요법으로, 특정 돌연변이를 가진 환자에서 잔존 효소의 안정성과 기능을 향상시키는 것입니다. FDA가 승인한 최초의 샤페론 치료제인 미갈라스타트(갈라폴드)는 ERT를 대체할 수 있는 경구용 약물로, 편의성이 높고 정맥주입과 관련된 합병증을 줄여줍니다. 또한, Gb3의 생성을 제한하고 질병의 진행을 늦추는 방법으로 기질감소요법(SRT)이 검토되고 있습니다. 이러한 치료법은 ERT가 잘 듣지 않는 환자나 경구용 약물을 선호하는 환자들에게 대체 요법을 제공합니다.

패브리병 치료 시장에는 어떤 도전과 기회가 존재할까?

큰 진전에도 불구하고, 파브리병 치료에는 몇 가지 과제가 남아있습니다. 가장 큰 장애 중 하나는 증상이 다른 일반적인 질환으로 오인되는 경우가 많기 때문에 조기 진단입니다. 많은 환자들이 적절한 치료를 받지 못해 돌이킬 수 없는 장기 손상을 초래하고 있습니다. 유전자 선별검사 프로그램과 신생아 선별검사 노력을 강화하는 노력은 조기 발견과 예후 개선을 위해 매우 중요합니다.

또 다른 과제는 치료 접근성과 저렴한 치료비입니다. 파브리병 치료, 특히 ERT와 유전자 치료는 매우 비싸기 때문에 종합적인 의료보험에 가입하지 않은 많은 환자들은 접근하기 어렵습니다. 이에 따라 희귀질환 치료에 대한 상환 정책 및 재정 지원을 지원하는 환자 옹호 단체 및 정부 이니셔티브가 증가하고 있습니다. 또한, 제약사들은 비용 효율적인 대안을 제공하고 치료 효과를 높이기 위해 바이오시밀러와 차세대 효소 요법을 모색하고 있습니다.

파브리병 치료 시장의 성장을 촉진하는 요인은 무엇일까?

파브리병 치료 시장의 성장은 유전자 치료의 기술 발전, 경구용 치료제 채택 증가, 희귀질환 연구 프로그램 확대 등 여러 요인에 의해 주도되고 있습니다. 새로운 치료제에 대한 규제 당국의 승인과 패스트트랙 지정이 증가함에 따라 의약품 개발이 가속화되고 있으며, 새로운 치료법을 더 빠른 속도로 이용할 수 있게 되었습니다. 또한, 제약사와의 공동 연구 및 제휴를 통해 혁신을 촉진하고, 현재 치료법의 한계를 극복할 수 있는 차세대 치료법 개발로 이어지고 있습니다.

인식 개선 캠페인과 유전자 검사의 발전도 조기 진단과 치료 시작을 가능하게함으로써 시장을 확대하고 있습니다. 또한, 신흥 시장에서의 의료 인프라 확충은 파브리병 치료에 대한 접근성을 향상시켜 더 많은 환자들이 적시에 효과적인 치료를 받을 수 있도록 돕고 있습니다. 연구가 진행됨에 따라 CRISPR 기반 유전자 편집, 첨단 생물학적 제제, 맞춤형 의료 접근법의 통합은 환자 결과 개선과 장기적인 질병 관리를 제공함으로써 상황을 변화시킬 것으로 예상됩니다.

부문

치료(효소보충요법, 샤프롱 치료, 기질 감소 치료, 기타 파브리병 치료), 투여 경로(정맥내 경로, 경구 경로), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업 사례

  • 4D Molecular Therapeutics
  • Amicus Therapeutics, Inc.
  • AVROBIO, Inc.
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Codexis, Inc.
  • Freeline Therapeutics Holdings PLC
  • Genzyme Corporation(Sanofi Genzyme)
  • Greenovation Biotech GmbH
  • Idorsia Pharmaceuticals Ltd
  • ISU Abxis Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • M6P Therapeutics
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Yuhan Corporation

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.06

Global Fabry Disease Treatment Market to Reach US$4.4 Billion by 2030

The global market for Fabry Disease Treatment estimated at US$2.7 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Chaperone Treatment segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$737.8 Million While China is Forecast to Grow at 13.2% CAGR

The Fabry Disease Treatment market in the U.S. is estimated at US$737.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$958.6 Million by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Fabry Disease Treatment Market - Key Trends & Drivers Summarized

What Is Fabry Disease and Why Is Effective Treatment Crucial?

Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, leading to a deficiency of the alpha-galactosidase A (α-Gal A) enzyme. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3). When the enzyme is deficient or completely absent, harmful lipid accumulation occurs in vital organs such as the heart, kidneys, and nervous system, leading to life-threatening complications. Fabry disease is progressive, meaning early and effective treatment is critical to managing symptoms, slowing organ damage, and improving patients' quality of life.

Fabry disease treatments primarily focus on replacing or enhancing the missing enzyme, slowing disease progression, and managing associated symptoms. Historically, Enzyme Replacement Therapy (ERT) has been the standard of care, with FDA-approved treatments such as agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme) helping to reduce Gb3 accumulation. However, limitations such as high costs, immune responses, and frequent intravenous infusions have driven the development of alternative therapies, including chaperone therapy and substrate reduction therapy (SRT). The recent introduction of gene therapy is also paving the way for a potential one-time treatment approach, offering hope for long-term disease management.

How Are Advancements in Gene and Molecular Therapy Transforming Fabry Disease Treatment?

Gene therapy is emerging as one of the most promising frontiers in Fabry disease treatment. Unlike traditional enzyme replacement therapy, gene therapy aims to correct the underlying genetic defect by delivering functional copies of the GLA gene into patient cells. Clinical trials are already showing promising results, with investigational therapies such as FLT190 and AVROBIO's AVR-RD-01 demonstrating sustained enzyme activity and reduced Gb3 levels. These therapies hold the potential for a one-time curative solution, eliminating the need for lifelong enzyme infusions.

Another major innovation in treatment is pharmacological chaperone therapy, which enhances the stability and function of the residual enzyme in patients with specific mutations. The first FDA-approved chaperone therapy, migalastat (Galafold), offers an oral alternative to ERT, providing greater convenience and reducing infusion-related complications. Additionally, substrate reduction therapies (SRTs) are being explored as a way to limit the production of Gb3, thereby slowing disease progression. These therapies provide an alternative for patients who do not respond well to ERT or prefer oral medications.

What Challenges and Opportunities Exist in the Fabry Disease Treatment Market?

Despite significant advancements, several challenges remain in Fabry disease treatment. One of the biggest obstacles is early diagnosis, as symptoms are often mistaken for other common conditions. Many patients experience delays in receiving proper treatment, leading to irreversible organ damage. Efforts to enhance genetic screening programs and newborn screening initiatives are crucial to identifying cases earlier and improving outcomes.

Another challenge is treatment accessibility and affordability. Fabry disease treatments, particularly ERT and gene therapy, are extremely expensive, making them inaccessible to many patients without comprehensive healthcare coverage. This has led to an increase in patient advocacy and government initiatives to support reimbursement policies and funding for rare disease treatments. Additionally, pharmaceutical companies are exploring biosimilar and next-generation enzyme therapies to provide cost-effective alternatives and enhance treatment efficacy.

What Is Driving Growth in the Fabry Disease Treatment Market?

The growth in the Fabry disease treatment market is driven by several factors, including technological advancements in gene therapy, the increasing adoption of oral therapies, and the expansion of rare disease research programs. The rise in regulatory approvals and fast-track designations for novel treatments has accelerated drug development, making new therapies available at a faster pace. Furthermore, pharmaceutical collaborations and partnerships are fostering innovation, leading to the development of next-generation therapies that address the limitations of current treatments.

Increasing awareness campaigns and genetic testing advancements are also expanding the market by enabling earlier diagnosis and treatment initiation. Additionally, expanded healthcare infrastructure in emerging markets is improving access to Fabry disease therapies, ensuring that more patients receive timely and effective treatment. As research progresses, the integration of CRISPR-based gene editing, advanced biologics, and personalized medicine approaches is expected to revolutionize the Fabry disease treatment landscape, offering better patient outcomes and long-term disease control.

SCOPE OF STUDY:

The report analyzes the Fabry Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy, Other Fabry Disease Treatment); Administration Route (Intravenous Route, Oral Route); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • 4D Molecular Therapeutics
  • Amicus Therapeutics, Inc.
  • AVROBIO, Inc.
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Codexis, Inc.
  • Freeline Therapeutics Holdings PLC
  • Genzyme Corporation (Sanofi Genzyme)
  • Greenovation Biotech GmbH
  • Idorsia Pharmaceuticals Ltd
  • ISU Abxis Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • M6P Therapeutics
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Yuhan Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Fabry Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Fabry Disease Due to Improved Genetic Testing Drives Demand for Specialized Therapies
    • Growth in Enzyme Replacement Therapies (ERT) and Oral Chaperone Treatments Expands Therapeutic Options
    • Increasing Regulatory Approvals of New Molecules and Biologics Strengthens Market Innovation
    • Expansion of Patient Support and Advocacy Programs Enhances Early Diagnosis and Access to Treatment
    • Rising R&D in Gene Therapy and mRNA Platforms Throws the Spotlight on Long-Term Disease-Modifying Approaches
    • Global Awareness Campaigns for Rare and Lysosomal Storage Disorders Fuel Fabry Disease Identification
    • Development of Pediatric-Specific Formulations and Dosing Regimens Promotes Age-Appropriate Care
    • Availability of Biomarker-Based Monitoring Supports Personalized Dosing and Disease Progression Management
    • Expansion of Specialty Pharmacies and Hospital Networks Improves Geographic Reach of Therapies
    • Collaborations Between Pharma Companies and Research Institutions Accelerate Novel Therapy Development
    • Shift From Intravenous to Oral Therapies Improves Patient Compliance and At-Home Care Models
    • Growing Pipeline of Fabry Disease Candidates With Improved Safety Profiles Enhances Clinical Acceptance
    • Increased Use of Real-World Evidence and Longitudinal Data Strengthens Health Outcomes Analysis
    • Rising Prevalence of Misdiagnosed Cases Promotes Multi-Specialty Diagnostic Pathways and Physician Education
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fabry Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chaperone Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chaperone Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chaperone Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Substrate Reduction Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Intravenous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Fabry Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Fabry Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Fabry Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Fabry Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제